BlackRock
CLRB icon

BlackRock’s Cellectar Biosciences CLRB Stock Holding History

BlackRock’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2K Sell
4,735
-10
-0.2% -$28 ﹤0.01% 5407
2026
Q1 		$12.1K Hold
4,745
– – ﹤0.01% 5378
2025
Q4 		$14K Hold
4,745
– – ﹤0.01% 5263
2025
Q3 		$26.6K Buy
4,745
+3
+0.1% +$15 ﹤0.01% 5099
2025
Q2 		$33.7K Sell
4,742
-2,952
-38% -$25.8K ﹤0.01% 5061
2025
Q1 		$72.8K Sell
7,694
-56
-0.7% -$507 ﹤0.01% 4840
2024
Q4 		$69.5K Buy
7,750
+6
+0.1% +$277 ﹤0.01% 4866
2024
Q3 		$497K Buy
7,744
+113
+1% +$7.45K ﹤0.01% 4330
2024
Q2 		$572K Buy
7,631
+2,885
+61% +$277K ﹤0.01% 4313
2024
Q1 		$567K Buy
4,746
+2,845
+150% +$308K ﹤0.01% 4340
2023
Q4 		$158K Hold
1,901
– – ﹤0.01% 4693
2023
Q3 		$151K Hold
1,901
– – ﹤0.01% 4748
2023
Q2 		$111K Hold
1,901
– – ﹤0.01% 4879
2023
Q1 		$81.6K Hold
1,901
– – ﹤0.01% 5007
2022
Q4 		$97.5K Hold
1,901
– – ﹤0.01% 5050
2022
Q3 		$192K Sell
1,901
-14
-0.7% -$2.01K ﹤0.01% 4990
2022
Q2 		$232K Sell
1,915
-461
-19% -$65.8K ﹤0.01% 4996
2022
Q1 		$489K Sell
2,376
-23
-1% -$4.03K ﹤0.01% 4873
2021
Q4 		$478K Buy
2,399
+23
+1% +$5.54K ﹤0.01% 4880
2021
Q3 		$659K Sell
2,376
-11
-0.5% -$3.36K ﹤0.01% 4679
2021
Q2 		$852K Buy
2,387
+21
+0.9% +$9.11K ﹤0.01% 4563
2021
Q1 		$1.14M Hold
2,366
– – ﹤0.01% 4460
2020
Q4 		$1.48M Buy
+2,366
New +$1.09M ﹤0.01% 4122
2020
Q3 		– Hold
0
– – – 5051
2020
Q2 		– Hold
0
– – – 5013
2020
Q1 		– Hold
0
– – – 4967
2019
Q4 		– Hold
0
– – – 4983
2019
Q3 		– Hold
0
– – – 4983
2019
Q2 		– Hold
0
– – – 5016
2019
Q1 		– Hold
0
– – – 4933
2018
Q4 		– Hold
0
– – – 4963
2018
Q3 		– Hold
0
– – – 5003
2018
Q2 		– Hold
0
– – – 5017
2018
Q1 		– Hold
0
– – – 4843
2017
Q4 		– Hold
0
– – – 4845
2017
Q3 		– Hold
0
– – – 4879
2017
Q2 		– Hold
0
– – – 4936
2017
Q1 		– Hold
0
– – – 4926

Other funds holding CLRB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock's CLRB Position: Q2 2026 in Review

BlackRock reduced its Cellectar Biosciences (CLRB) stake by 0.21% in Q2 2026, selling an estimated $28 and leaving 4,735 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5407.

BlackRock first reported a position in CLRB in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.48M in Q4 2020. 18 funds tracked by Wall St. Rank hold CLRB as of Q2 2026.

  • BlackRock held 4,735 shares of Cellectar Biosciences worth $13.2K as of Q2 2026.
  • BlackRock sold 10 Cellectar Biosciences shares in Q2 2026, an estimated $28.
  • Cellectar Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5407 holding.
  • BlackRock first reported a position in Cellectar Biosciences in Q4 2020 and has held it in 23 quarters since.
  • BlackRock's Cellectar Biosciences position peaked at $1.48M in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.